US › Healthcare

Profound Medical Corp (PROF)

US · Healthcare · Medical Devices

$6.01-4.75%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$2.5M

Revenue YoY

+12.3%

Net profit

$-9.5M

EPS

$0.26

EPS estimate

$-0.22

Net margin

-384.2%

EPS came in at 0.26 against a street estimate of -0.22 — a beat of 218.2%.

Key statistics

Market cap

$256.1M

Forward P/E

0.0

P/B

4.19

Book value

$1.36

EPS (TTM)

$-0.99

52-week high

$8.95

52-week low

$4.80

50-day MA

$6.58

200-day MA

$6.80

Beta

0.56

Analyst view

Analysts rate Profound Medical Corp a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.14.

Shareholding

Insiders

4.09%

Institutions

44.98%

Largest institutional holders

Fund	Stake
Fidelity International Ltd	6.49%
Gagnon Securities LLC	5.36%
Royce & Associates, LP	3.28%
Timelo Investment Management Inc.	3.05%
Gagnon Advisors, LLC	2.63%
Letko, Brosseau & Associates Inc.	2.56%
Arnhold & S. Bleichroeder Advisers, LLC	2.41%
Rosalind Advisors, Inc.	2.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Profound Medical Corp — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.